Supplementary Table 1 Baseline characteristics of the CrAg-positive and CrAg-negative patients

|  |  |  |  |
| --- | --- | --- | --- |
|  | CrAg+ n=67 | CrAg- n=134 | P |
| Age (median, IQR) | 39 (32-47) | 39 (33–48) | 0.63\* |
| Female (%) | 37 (55) | 62 (46) | 0.23 |
| Self-assigned Black race (%) | 66 (99) | 128 (96) | 0.4 |
| Born outside of SA1 (%)  | 28 (42) | 33 (25) | 0.01 |
| Non-SADC (%) | 3 (5) | 3 (2) | 0.4 |
| CD4 cells/µL (median, IQR) | 27 (7–40) | 41 (16–64) | 0.002\* |
|  <50 (%) |  55(82) |  80 (60) | 0.001 |
| BMI <18 kg/m2 (%)2 | 9 (20) | 20(18) | 1.0\*\* |
| Hemoglobin ≤8g/dl (%)3 | 5 (9) | 13 (11) | 0.8\*\* |
| CRP mg/L (median, IQR)4 | 15 (3-49) | 22 (4-56) | 0.4 |
| Other (not TB) previous or current ADI (%) | 11 (16) | 20 (15) | 0.8\*\* |
| Histoplasmosis5 | 3 (5) | 3 (2) | 0.4\*\* |
| Other (non-ADI) medical conditions (%) | 30 (45) | 57 (43) | 0.8 |
| Infectious disease (%) | 18 (27) | 39 (29) | 0.7 |
| Hepatitis B6 | 6(17) | 11(13) | 0.6\*\* |
| Immunocompromising (%) | 2 (3) | 4 (3) | 1.0\*\* |
| Taking ART (>1 day) (%) | 16 (24) | 13 (10) | 0.01\*\* |
| Taking co-trimoxazole (%) | 37 (55) | 32 (24) | <0.001 |
| Taking other antibiotics (%) | 22 (33) | 37 (28) | 0.4 |

Abbreviations: CrAg = cryptococcal antigen; IQR = interquartile range; SA = South Africa; SADC = Southern Africa Development Community; CD4 = CD4 T-lymphocyte count; ART = antiretroviral therapy; BMI = body mass index; CRP= C-reactive protein; TB = tuberculosis; ADI = AIDS defining illness.

Data missing on: birthplace for 1 patient1; BMI for 20 CrAg-positive and 23 CrAg-negative patients2; hemoglobin for 12 CrAg-positive and 15 CrAg-negative patients3; CRP for 5 CrAg-positive and 5 CrAg-negative patients4; histoplasmosis screening (urine enzyme immunoassay (IMMY) for 1 CrAg-positive and 7 CrAg-negative patients5; hepatitis B for 32 CrAg-positive and 50 CrAg-negative patients6.

\* Mann-Whitney U test

\*\* Fisher’s Exact Test

Pearson’s chi square test used unless indicated.

Supplementary Table 2 Number and proportion of CrAg-positive and CrAg-negative patients who reported a diagnosis of TB prior to CrAg screening, or who had prevalent TB (diagnosed within the past 2 months or on the day of attendance for CrAg result)

|  |  |  |  |
| --- | --- | --- | --- |
|  | CrAg+ (67) | CrAg- (134) | Total (201) |
| Prior TB >2 months prior to CrAg screening | 15 (22.4%) | 14 (10.5%) | 29 (14.4%) |
| Diagnosed >2 and ≤6 months prior to CrAg screening | 3 (4.5%) | 1 (0.8%) | 4 (2.0%) |
| Diagnosed >6 and ≤24 months prior to CrAg screening | 3 (4.5%) | 2 (1.5%) | 5 (2.5%) |
| Diagnosed >24 months prior to CrAg screening | 9 (13.4%) | 11 (8.2%) | 20 (10.0%) |
| Prevalent TB | 15 (22%) | 32 (24%) | 47 (23%) |
| Diagnosed <=2 months prior to CrAg screening | 7 (10%) | 11 (8%) | 18 (9%) |
| Diagnosed on day of attendance for CrAg result | 8 (12%) | 21 (16%) | 29 (62%) |

Abbreviations: CrAg, cryptococcal antigen; CrAg+, positive; CrAg-, negative; TB, tuberculosis